Collins, D. M., Conlon, N. T., Kannan, S., Verma, C. S., Eli, L. D., Lalani, A. S., & Crown, J. (2019). Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer. Cancers (Basel).
Chicago Stili AlıntıCollins, Denis M., Neil T. Conlon, Srinivasaraghavan Kannan, Chandra S. Verma, Lisa D. Eli, Alshad S. Lalani, ve John Crown. "Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared With Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer." Cancers (Basel) 2019.
MLA AlıntıCollins, Denis M., et al. "Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared With Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer." Cancers (Basel) 2019.